Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transvaginal BTA for IC/BPS
NCT05485207Phase 1Active, not recruiting
- Sponsor
- Stanford University
- Start
- Apr 2022
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of botulinum toxin type A in interstitial cystitis (IC) and bladder pain syndrome (BPS), sponsored by Stanford University. Primary endpoint: Patient Global Impression of Change at 12 weeks. Started Apr 2022; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
interstitial cystitis (IC)bladder pain syndrome (BPS)
Beyond the preview
Go deeper on NCT05485207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485207.